Bioray Biotech Co (7561) Fair Value & Analysis
Healthcare · TW · Market cap 567M TWD
Fair value as of: Jun 24, 2026
Analysis
Bioray Biotech Co (7561) currently trades at 19.15 TWD, while our model-based Fair Value estimate is 21.80 TWD — implying the stock looks roughly 13.8% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Bioray Biotech Co., Ltd engages in the production, research, and sells health foods, immune cell products, and precision testing services in Taiwan. It offers health care products, including various functional foods and supplements; medicinal fungi; immune cell products; and precision medicine services, such as immunology, cell division, and specialized laboratory testing. The company is also involved in the cell testing and storage business. Bioray Biotech Co., Ltd was founded in 2005 and is based in Tainan City, Taiwan.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Bioray Biotech Co (7561) undervalued?
What is the fair value of 7561?
What is the quality score of 7561?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.